All News

Would would happen if I turned my back to the past and faced forward? It is time to stop wishing I could go back to my pre-cancer life. It's time to face forward.

Cancer survivor encourages fellow survivors to cultivate hope to improve their survivorship time.

Here are the top 5 CURE stories for October 2018.

I may be down one ball, but I've increased in many other ways

Remembering a loved one's spirit in a new way can bring healing and hope.

The immunotherapy agent received approval for the treatment of metastatic squamous non-small cell lung cancer.

The PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase 3 SOLO-1 trial presented at the 2018 ESMO Congress.

Metastatic breast cancer advocate goes to Washington DC to tell her own story and push for more research to be directed toward metastatic disease

How I battle the beast of breast cancer.

People with slow-growing B-cell lymphomas and no symptoms are often prescribed a watch-and-wait approach, which involves monitoring until the disease grows and warrants treatment.

Treating older patients who have Hodgkin lymphoma with Adcetris (brentuximab vedotin) before and after chemotherapy showed improved remission and survival rates, according to phase 2 study findings.

Cancer can affect all areas of life, in both good and bad ways.

The mammogram can be an emotional roller coaster for any person. After you have been diagnosed with breast cancer, even good results can tap into deep emotions.

I stepped out of my comfort zone to share my cancer story.

A cancer diagnosis can bring many fears and uncertainties to the forefront, but it can also bring friendships with people we would never have met had we not gotten cancer at all.

Though it's a weird thing to say, I'm posting this to help you realize that if you "miss having cancer," you're not the only one.

The Food and Drug Administration has granted a priority review to the supplemental new drug application for Jakafi (ruxolitinib) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.

The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application for Lonsurf (TAS-102; trifluridine/tipiracil) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.

After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.

For many patients with polycythemia vera, hydroxyurea is a beneficial first-line treatment. But that’s not the case for everyone. One expert discusses which drugs should be used next.

The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.

Advice for the inoperable facing a lifetime of treatment.

Understanding the type of MPN can affect how care is carried out and how well it may work.

A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.

Preliminary findings showed that Revlimid (lenalidomide) significantly prolonged progression-free survival compared with observation in patients with smoldering multiple myeloma.

The anti-PD-1 monoclonal antibody TSR-042 may be safe and effective for the treatment of patients with microsatellite-high (MSI-H) endometrial cancer.